Headquartered in Salt Lake City, UT·Fiscal year ends December·NASDAQ: CODX·co-dx.com
About Co-Diagnostics
Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company built on a patented Co-Primers technology for designing tests that detect and analyze nucleic acids (DNA or RNA).
- **Current sales:** Revenue comes from product sales. This includes the Vector Smart laboratory equipment, consumables and reagents used for mosquito pool PCR surveillance. Vector Smart serves customers across 21 U.S. states and was recently deployed internationally at a U.S. Air Force base.
- **Pipeline platform:** The company's main development focus is the Co-Dx PCR at-home and point-of-care platform, which includes the PCR Home and PCR Pro instruments, a mobile app and associated tests. The platform is not yet available for sale.
- **Regulatory filings:** A Flu A/B & RSV test is under FDA 510(k) and CLIA waiver review. A point-of-care tuberculosis test (CoSara PCR MTB) is under review by India's CDSCO through CoSara Diagnostics, a joint venture.
- **Other development work:** The company is developing Ebola and Bundibugyo virus assays, including plasma-based testing in collaboration with ReadyGo Diagnostics. It has also launched cloud and mobile data infrastructure in India.
- **Partners:** It works with joint ventures and partners such as CoSara and CoMira on manufacturing and international commercialization. Updated
Wednesday afternoon's top analyst upgrades and downgrades included Inovio Pharmaceuticals, McDonald’s, Orchard Therapeutics, VBI Vaccines and Wingstop.
Tuesday's top analyst upgrades and downgrades included AECOM, BBVA, Cheniere Energy, Chevron, DraftKings, General Motors, Moderna, Novavax, Palo Alto Networks and Penn National Gaming.
Co-Diagnostics announced Tuesday that it has entered into an agreement with Arches Research to expand Arches' COVID-19 testing services using Co-Diagnostics’ test kit.
Friday's top analyst upgrades and downgrades included AES, Applied Materials, Bloom Energy, Chimera Investment, Co-Diagnostics, FirstEnergy, Home Depot, Marriott, Target, Tesla and Walmart.
Wednesday's top analyst upgrades and downgrades included AbbVie, American Electric Power, Anheuser-Busch InBev, Arconic, Baidu, Best Buy, Co-Diagnostics, Cree, Exelon, Home Depot, NRG Energy, T-Mobile and Walmart.
Monday's top analyst upgrades and downgrades included Apple, Best Buy, Cinemark, Co-Diagnostics, DraftKings, Energizer, Novavax, Nvidia, Palo Alto Networks and Petrobras.
This specialty pharmaceutical company is making good progress on multiple fronts, including changes to its board of directors and with its test for and treatment of COVID-19.
Aytu BioScience has been one of the biggest winners in the fight against the novel coronavirus. The company is sending 2,700 COVID-19 rapid tests to Denver for use with first responders.
GenMark Diagnostics shares shot up early on Wednesday after the company provided an update on its quarterly numbers and where it stands with its coronavirus test.
Becton, Dickinson is officially throwing its hat in the ring to fight COVID-19. Specifically, this firm is working on the front end by testing for the disease and antibodies that have been…
Co-Diagnostics, Inc. (Nasdaq: CODX) is a molecular diagnostics company built on a patented Co-Primers technology for designing tests that detect and analyze nucleic acids (DNA or RNA). - **Current sales:** Revenue comes from product sales.
What is the CODX stock price target?
The Wall Street consensus 12-month price target for CODX is $4.00.